Stanley Medical Research Institute

NCT04093518

Collaborator, Phase 3, Status unknown, 2019, 100 people, 18 Sept 2019, clinicaltrials.gov

NCT03848234

Collaborator, Phase 3, Completed, 2015, 209 people, 20 Feb 2019, clinicaltrials.gov

NCT02880462

Collaborator, Phase 2, Completed, 2016, 172 people, 26 Aug 2016, clinicaltrials.gov

NCT02703363

Collaborator, Phase 3, Completed, 2016, 265 people, 9 Mar 2016, clinicaltrials.gov

NCT02685748

Collaborator, Phase 2/3, Completed, 2017, 60 people, 19 Feb 2016, clinicaltrials.gov

NCT02519543

Collaborator, Phase 3, Completed, 2015, 50 people, 11 Aug 2015, clinicaltrials.gov

NCT02456454

Collaborator, Phase 3, Completed, 2006, 46 people, 28 May 2015, clinicaltrials.gov

NCT02417142

Collaborator, Phase 4, Completed, 2014, 70 people, 15 Apr 2015, clinicaltrials.gov

NCT02197286

Collaborator, Phase 2, Withdrawn, 2015, 0 people, 22 Jul 2014, clinicaltrials.gov

NCT02104752

Collaborator, Phase 1/2, Completed, 2014, 39 people, 4 Apr 2014, clinicaltrials.gov

NCT02034474

Collaborator, Phase 4, Completed, 2014, 59 people, 13 Jan 2014, clinicaltrials.gov

NCT01999309

Collaborator, Phase 3, Completed, 2013, 121 people, 3 Dec 2013, clinicaltrials.gov

NCT01809158

Collaborator, Phase 4, Completed, 2013, 150 people, 12 Mar 2013, clinicaltrials.gov

NCT01797575

Collaborator, Phase 2, Completed, 2013, 38 people, 22 Feb 2013, clinicaltrials.gov

NCT01602029

Collaborator, Phase 2, Completed, 2010, 303 people, 18 May 2012, clinicaltrials.gov

NCT01573637

Collaborator, Phase 3, Completed, 2011, 78 people, 9 Apr 2012, clinicaltrials.gov

NCT01479829

Collaborator, Phase 4, Completed, 2011, 100 people, 24 Nov 2011, clinicaltrials.gov

NCT01429272

Collaborator, Phase 3, Completed, 2011, 99 people, 7 Sept 2011, clinicaltrials.gov

NCT01409096

Collaborator, Phase 4, Completed, 2010, 80 people, 3 Aug 2011, clinicaltrials.gov

NCT01339858

Collaborator, Phase 4, Completed, 2011, 60 people, 21 Apr 2011, clinicaltrials.gov

Exploring Diabetes Risk Link to Insulin Resistance and Immunity–Inflammation Index in Cohort of Schizophrenia: Effects of Ginsena-115 Targeting GLP–Inflammasome Signaling

ADA Scientific Sessions 2026 abstract, 5 Jun 2026